Individualized survival and treatment response predictions for breast cancers using phospho-EGFR, phospho-ER, phospho-HER2/neu, phospho-IGF-IR/In, phospho-MAPK, and phospho-p70S6K proteins

International Journal of Biological Markers

Volumn 22, Issue 1, 2007, Pages 1-11

  Guo, Lan ^a   Abraham, J ^b   Flynn, D C ^a   Castranova, V ^c   Shi, X ^c   Qian, Yong ^c  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

Author keywords

Active protein kinase; Breast cancer; Prediction; Survival; Treatment responses

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOPROTEIN; PROTEIN KINASE; PROTEIN P70; SOMATOMEDIN C RECEPTOR;

ACCURACY; ADULT; AGED; ALGORITHM; ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL DECISION MAKING; DISEASE FREE SURVIVAL; ENZYME ACTIVATION; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PARTIAL MASTECTOMY; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

EID: 34248395854     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.3686     Document Type: Article

References (19)

1. Murphy N, Millar E, Lee CS. Gene expression profiling in breast cancer: towards individualising patient management. Pathology 2005; 37: 271-7.
2. Rosen JM. Hormone receptor patterning plays a critical role in normal lobuloalveolar development and breast cancer progression. Breast Dis 2003; 18: 3-9.
3. Witten IH, Frank E. Data mining: Practical machine learning tools and techniques (2nd edition). San Francisco: Morgan Kaufmann 2005.
4. Warlord A. Tissue microarrays: fast-tracking protein expression at the cellular level. Expert Rev Proteomics 2004; 1: 283-92.
5. Warlord A, Howat W, McCafferty J. Expression profiling by high-throughput immunohistochemistry. J Immunol Methods 2004; 290: 81-92.
6. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
7. Kallakury BV, Sheehan CE, Ambros RA, et al. Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/ neu oncogene amplification with recurrence in prostatic adenocarcinomas. J Clin Oncol 1998; 16: 1302-9.
8. Ouban A, Muraca P, Yeatman T, Coppola D. Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum Pathol 2003; 34: 803-8.
9. Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993; 85: 200-6.
10. American Joint Committee on Cancer Staging Manual, 5th ed. Philadelphia, PA: Lippincott-Raven 1997.
11. Zaczek A, Brandt B, Bielawski KP The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches. Histol Histopathol 2005; 20: 1005-15.
12. Atalay G, Cardoso F, Awada A, Piccart MJ. Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. Ann Oncol 2003; 14: 1346-63.
13. Ross JS, Linette GP, Stec J, et al. Breast cancer biomarkers and molecular medicine. Expert Rev Mol Diagn 2003; 3: 573-85.
14. Gee JM, Robertson JF, Ellis I0, Nicholson RI. Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 2001; 95: 247-54.
15. Mita MM, Mita A, Rowinsky EK. The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol Ther 2003; 2 (4 Suppl 1): 5169-77.
16. Bunone G, Briand PA, Miksicek RJ, Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 1996; 15: 2174-83.
17. Hutcheson IR, Knowlden JM, Madden TA, et al. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Res Treat 2003; 81: 81-93.
18. Lonning PE, Helle SI. IGF-1 and breast cancer. Novartis Found Symp 2004; 262: 205-12.
19. Surmacz E, Bartucci M. Role of estrogen receptor alpha in modulating IGF-1 receptor signaling and function in breast cancer. J Exp Clin Cancer Res 2004; 23: 385-94.